CryoPort, Inc. to Ship Clinical Specimens for Quest Diagnostics

LAKE FOREST, CA -- (MARKET WIRE) -- 10/22/08 -- CryoPort, Inc. (OTCBB: CYRX) today announced that it has reached an agreement to begin shipping frozen specimens for Quest Diagnostics. This is the initial phase of a multi-stage program. This first phase involves shipments made for Quest Diagnostics Clinical Trials from their laboratory in Gurgaon, India to multiple locations in the U.S. The shipments will be sent using the CryoPort Express(TM) One-Way Shipper and their transportation will be managed by Federal Express.

Peter Berry, CEO of CryoPort, commented, "We see increasing opportunities in India and other areas of the developing world to leverage the safer, longer holding times of the CryoPort Express(TM) Shipper in complex shipping routes. This is an exciting first step in the roll out of our service with this important customer."

To be added to the CryoPort Investor email list, please email edward@carpedminc.com with CYRX in the subject line.

About CryoPort, Inc.

CryoPort (www.cryoport.com) develops leading edge, proprietary, technology-driven shipping and storage products for use in the rapidly growing global biotechnology and biopharmaceutical cold chain. The products developed by CryoPort are essential components of the infrastructure required for the testing, research and end user delivery of temperature-sensitive medicines and biomaterials in an increasingly complex logistical environment.

"SAFE HARBOR"

This press release contains forward-looking statements. The words "estimate," "possible" and "seeking" and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact:
Stuart Fine
Carpe DM, Inc.
908-469-1788

Released October 22, 2008